Duchenne Muscular Dystrophy (DMD)GUP23005NCT07890883
Bone Health in Adults With Duchenne Muscular Dystrophy: A Survey on Osteoporosis, Fractures and Treatment.
An observational study of Duchenne Muscular Dystrophy (DMD), run by Istituto Giannina Gaslini at 15 sites in Italy.
Trial summary
Background and Rationale Duchenne muscular dystrophy (DMD) is a genetic disorder caused by mutations in the dystrophin gene, resulting in progressive muscle weakness and multiple complications, including respiratory and cardiac impairment, osteoporosis (OP), and fragility fractures (FF). Read more about this study
- Who is it for?
- Ages 18 to 44 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Duchenne Muscular Dystrophy (DMD)
- How many people
- 200 participants
- Where
- 15 sitesItaly
- Study dates
- 11 Apr 2024to 31 Dec 2026
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 44 years
- Men only
- Healthy volunteers accepted
- Adult
Study population: The study population will include approximately 200 adult patients with Duchenne muscular dystrophy (DMD), aged over 18 years, recruited from 15 Italian tertiary referral centers specializing in neuromuscular diseases. A control group of 50 healthy male subjects aged over 18 years will be recruited exclusively at IRCCS Istituto Giannina Gaslini for serum biomarker analysis.
Who may be able to join
- Genetic or histological diagnosis of Duchenne muscular dystrophy (DMD).
- Age over 18 years.
- Willingness to participate in the study and provision of written informed consent.
Who cannot join
- Current enrollment in another clinical study.
- Inability to undergo dual-energy X-ray absorptiometry (DXA) due to severe kyphoscoliosis.
- Previous surgery for scoliosis.
- Severe respiratory failure, defined as the need for non-invasive ventilation (NIV) 24 hours per day or the presence of a tracheostomy.
- Severe cardiomyopathy, defined as a left ventricular ejection fraction (LVEF) below 30%.
- Severe intellectual disability (IQ below 45) and inability to perform functional assessments.
Trial locations and contacts
15 sites in 1 country. Contact the study team or a site near you to ask about taking part.
15 sites in 1 country
Italy15 sites, 15 recruiting
- Recruiting
Centro Malattie Neuromuscolari dell'età Evolutiva, Bologna
Bologna
Melania Giannotta, +39 051 4966159, npi.malattieneuromuscolari@ausl.bologna.it
- Recruiting
Associazione La Nostra Famiglia Eugenio Medea IRCCS, Bosisio Parini
Bosisio Parini
Eleonora Diella, +39 031 877829, polo.bosisio@lanostrafamiglia.it
- Recruiting
Associazione La Nostra Famiglia Eugenio Medea IRCCS, Conegliano
Conegliano, 31015
Massimo Cordini, +39 0438 4141, irccs@cn.lnf.it
- Recruiting
IRCCS Istituto Giannina Gaslini
Genova, 16147
Chiara Panicucci, +39 010 56362756, chiarapanicucci@gaslini.org
- Recruiting
Dipartimento di Scienze Cliniche e Sperimentali, Università di Brescia
Gussago
Massimiliano Filosto Massimiliano Filosto, +39 030 6729100, dscs@cert.unibs.it
- Recruiting
Azienda Universitaria Policlinico G. Martino
Messina
Sonia Messina, +39 090 221 7178, urp@polime.it
- Recruiting
Fondazione IRCCS Istituto. Neurologico "C. Besta", Milano
Milan
Lorenzo Maggi, +39 02 2394 2282, neurologia4@istituto-besta.it
- Recruiting
Università degli Studi di Milano Statale
Milan
Emilio Albamonte, +39 02 9143 371, info@centrocliniconemo.it
- Recruiting
Università degli Studi della Campania Luigi Vanvitelli, Napoli
Naples
Vincenzo Nigro, +39 081 566 5704, dip.medicinadiprecisione@unicampania.it
- Recruiting
Dipartimento di Neuroscienze Università di Padova
Padova
Luca Bello, +39 049 827 2025, dip.neuroscienze@unipd.it
- Recruiting
Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa
Pisa
Gabriele Siciliano, +39 050 993212, amb.neuromuscpisa@ao-pisa.toscana.it
- Recruiting
Fondazione Stella Maris IRCCS-Pisa
Pisa
Roberta Battini, +39 050 886282, lmalucelli@fsm.unipi.it
- Recruiting
Dipartimento di Neuroscienze IRCCS Ospedale Bambino Gesù, Roma
Roma
Michela Catteruccia, +39 06 6859 2105, neurologia@opbg.net
- Recruiting
Fondazione Policlinico Universitario Agostino Gemelli, Roma
Roma
Concetta Palermo, +39 06 3015 6391, pediatrico.roma@centrocliniconemo.it
- Recruiting
Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze, Siena
Siena
Diego Lopergolo, +39 0577 585760, neurometaboliche@ao-siena.toscana.it
About this study
Official title: Bone Health in Adult Patients With Duchenne Muscular Dystrophy: A Survey on Osteoporosis, Fractures, and Their Treatment.
Background and Rationale Duchenne muscular dystrophy (DMD) is a genetic disorder caused by mutations in the dystrophin gene, resulting in progressive muscle weakness and multiple complications, including respiratory and cardiac impairment, osteoporosis (OP), and fragility fractures (FF). Bone fragility is a major concern, as lower-limb fractures may accelerate the loss of independent ambulation and complicate daily care. Despite increased life expectancy, bone health in adults with DMD remains insufficiently investigated. This study aims to address this knowledge gap and improve the understanding and management of skeletal complications in this population.
Objectives
Read more
The study aims to: (1) determine the prevalence of fragility fractures in adults with DMD; (2) identify childhood and adolescent risk or protective factors affecting adult bone health; (3) collect data on fracture treatment; (4) measure serum analytes involved in bone metabolism and bone-muscle crosstalk; and (5) identify genetic modifiers associated with increased fracture risk.
Study Population
Approximately 200 patients with DMD aged over 18 years will be recruited from 15 Italian tertiary referral centers specializing in neuromuscular diseases. A control group of healthy males aged over 18 years will be recruited exclusively at the coordinating center. Controls will undergo only a blood collection of approximately 3 mL for serum analysis.
Study Design and Procedures Patients will undergo respiratory assessment, including peak expiratory flow (PEF), forced vital capacity (FVC), and respiratory support requirements; orthopedic assessment of scoliosis, contractures, deformities, and previous spinal fusion surgery; motor function assessment using the North Star Ambulatory Assessment (NSAA); upper-limb function assessment using the Performance of the Upper Limb (PUL) scale; and the Six-Minute Walk Test (6MWT). Imaging procedures will include a lateral thoracolumbar spine radiograph (T4-L4) and dual-energy X-ray absorptiometry (DXA) of the lumbar spine (L1-L4) and total body less head (TBLH). Clinical and medical history data will be recorded using a dedicated case report form (CRF).
Biological Samples and Analyses One blood sample of approximately 3 mL will be collected for serum extraction and analysis of metabolites involved in bone metabolism and bone-muscle crosstalk. Samples will be centralized at the coordinating center and then sent to the University of Campania "Luigi Vanvitelli" for analysis. Healthy control samples will be used for comparison.
Two additional blood tubes, totaling approximately 6 mL, will be collected for DNA extraction and genome-wide association studies (GWAS), aimed at identifying genetic modifiers associated with increased fracture risk. These samples will be centralized and subsequently sent to the University of Padua for genetic analysis.
Data Management and Ethics Study data will be anonymized and managed in accordance with the General Data Protection Regulation (GDPR, EU 2016/679) and the Declaration of Helsinki. Patients and/or their legally authorized representatives will receive the study information and provide written informed consent before participation. Investigators will declare any potential conflicts of interest.
Expected Outcomes The study will characterize bone health and fragility fracture prevalence in adults with DMD, describe fracture management, and investigate clinical, developmental, biochemical, and genetic factors associated with fracture risk. The findings may help improve fracture prevention, bone health monitoring, and clinical management in this population.
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Medical subject headings
- Muscular Dystrophy, Duchenne
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| DMD patients (study group) | Approximately 200 adult patients with Duchenne muscular dystrophy (DMD), aged over 18 years, recruited from 15 Italian centers. | |
| Healthy controls (control group) | Healthy male subjects aged over 18 years, recruited exclusively at IRCCS Istituto Giannina Gaslini, who will undergo only a blood sample collection of approximately 3 mL. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of Fragility Fractures in Adult Patients with DMD
To determine the prevalence of extremity fractures in adult patients with Duchenne muscular dystrophy based on review of clinical records.
Measured: Baseline
Secondary outcomes (16)
Prevalence of Vertebral Fractures in Adult Patients with DMD
To determine the prevalence of vertebral fractures in adult patients with Duchenne muscular dystrophy based on lateral thoracolumbar spine radiographs (T4-L4).
Measured: Baseline
Fracture Treatment Patterns
To describe the treatments administered for fragility fractures in adult patients with Duchenne muscular dystrophy.
Measured: Baseline
Serum Biomarkers of Bone Metabolism and Bone-Muscle Crosstalk
To measure serum analytes involved in bone metabolism and bone-muscle crosstalk in patients with DMD and compare their levels with those of healthy male controls.
Measured: Baseline
Genetic Modifiers Associated with Fracture Risk
To identify genetic variants potentially associated with an increased risk of fractures in patients with DMD through DNA analysis and genome-wide association studies (GWAS).
Measured: Baseline
Bone Mineral Density of the Lumbar Spine (L1-L4)
To assess bone mineral density at the lumbar spine (L1-L4) using dual-energy X-ray absorptiometry (DXA).
Measured: Baseline
Bone Mineral Density of Total Body Less Head (TBLH)
To assess bone mineral density of total body less head (TBLH) using dual-energy X-ray absorptiometry (DXA).
Measured: Baseline
Peak Expiratory Flow (PEF)
To assess respiratory function by measuring peak expiratory flow (PEF).
Measured: Baseline
Forced Vital Capacity (FVC)
To assess respiratory function by measuring forced vital capacity (FVC).
Measured: Baseline
Respiratory Support Status
To record respiratory support status at the study visit.
Measured: Baseline
Presence of Scoliosis
To record the presence of scoliosis based on the orthopedic assessment.
Measured: Baseline
Presence of Contractures
To record the presence of contractures based on the orthopedic assessment.
Measured: Baseline
Other Orthopedic Deformities
To characterize other orthopedic deformities identified during the orthopedic assessment.
Measured: Baseline
History of Arthrodesis
To record whether the patient has undergone an arthrodesis procedure, based on the clinical history and orthopedic assessment.
Measured: Baseline
Motor Function Assessed by NSAA
To assess motor function using the North Star Ambulatory Assessment (NSAA).
Measured: Baseline
Upper-Limb Function Assessed by PUL
To assess upper-limb motor function using the Performance of Upper Limb (PUL) scale.
Measured: Baseline
Walking Capacity Assessed by 6MWT
To assess walking capacity using the Six-Minute Walk Test (6MWT).
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Oct 2026
- Study start11 Apr 2024
- Primary completion28 Feb 2026
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Duchenne Muscular Dystrophy (DMD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Istituto Giannina Gaslini
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07890883
- Sponsor's protocol ID
- GUP23005 (13634)
- Acronym
- GUP23005
- Status last verified
- Oct 2026
- First submitted
- 9 Oct 2026
- Last updated
- 22 Oct 2026
- Results posted
- No
- Individual data sharing
- Undecided